- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Bcl-2 BH3 Domain Antibody Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP1303a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Bcl-2 BH3 Domain Antibody Blocking Peptide - Product info | |
| Primary Accession | P10415 |
| Clone Names | 2011005 |
| Calculated MW | 26266 Da |
Bcl-2 BH3 Domain Antibody Blocking Peptide - Additional info | |
| Gene ID 596 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP1303a was selected from the region of human Bcl-2 BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Bcl-2 BH3 Domain Antibody Blocking Peptide - Protein Information | |
| Name BCL2 | |
| Function Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1) | |
| Cellular Location Mitochondrion outer membrane; Single-pass membrane protein. Nucleus membrane; Single-pass membrane protein Endoplasmic reticulum membrane; Single-pass membrane protein | |
| Tissue Location Expressed in a variety of tissues. | |
Bcl-2 BH3 Domain Antibody Blocking Peptide - Related products
AP1303a: Bcl-2 Antibody (BH3 Domain Specific)
Bcl-2 BH3 Domain Antibody Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
BCL2 is integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends.
REFERENCES
Zhu, C.J., et al., J. Neurosci. Res. 74(1):60-66 (2003).Scopa, C.D., et al., Dig. Dis. Sci. 48(10):1990-1997 (2003).Grace, V.M., et al., Gynecol. Oncol. 91(1):51-58 (2003).Thoulouze, M.I., et al., Virology 314(2):549-561 (2003).Iwata, A., et al., J. Immunol. 171(6):3136-3141 (2003).
